Clinical trial
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease: A Randomized Controlled Trial
NCT07909915 is registered in ClinicalTrials.gov with Rehman Medical Institute - RMI as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, Phase 4, 178 participants (estimated). Lead sponsor Rehman Medical Institute - RMI; Pakistan. Primary measure: Achievement of LDL-C Target Levels. 5 linked papers (newest 2024).
How it compares
34 similar trials: same condition (Hypertriglyceridemia) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease: A Randomized Controlled Trial
- Lead sponsor
- Rehman Medical Institute - RMI
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- June 30, 2027
- Enrollment
- 178 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Dyslipidemias, Hypercholesterolemia, Hypertriglyceridemia, Stroke
Registry terms: cardio vascular disease, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, stroke (cva) or tia
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- Pakistan
- Lead sponsor
- Rehman Medical Institute - RMI
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| treat to target | Experimental | Dose adjustment of statins |
Show registry wordingrosuvastatin 10 mg or atorvastatin 20 mg ( to be adjusted as per response of patinet) | ||
| Fixed dose | Active comparator | no dose adjustment |
Show registry wordingfixed dose atorvastatin or rosuvastatin | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Achievement of LDL-C Target Levels. | 12 weeks |
Show registry wordingThe proportion of patients with elevated LDL-C who achieve the treatment goal of LDL-C levels \< 55 mg/dL (high risk) and \< 70 mg/dL (low risk) at 4 and 12 weeks of therapy. | |
Papers
PubMed papers this trial cites; 5 papers, results papers first, then newest first.
Lead sponsor's other trials
Rehman Medical Institute - RMI, most recent start first.
+18 more trials See the organization page
Similar trials
Same condition (Hypertriglyceridemia) and phase, most recent start first.
+29 more trials See the condition page